Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial
29. Oktober 2020 16:13 ET
|
Equillium
Equillium plans to initiate global Phase 3 COVID-19 trial – EQUINOX – during Q4 2020 FDA indicates study could support BLA filing LA JOLLA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Equillium,...
Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the European Respiratory Society International Congress 2020
17. September 2020 16:07 ET
|
Equillium
LA JOLLA, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients
15. September 2020 08:07 ET
|
Equillium
Equillium anticipates filing a U.S. IND for Itolizumab for COVID-19 and initiating a global Phase 3 clinical study in Q4 2020 LA JOLLA, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc....
Equillium to Present at H.C. Wainwright 22nd Annual Global Investment Conference
03. September 2020 16:07 ET
|
Equillium
LA JOLLA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium Announces Closing of Public Offering of Common Stock
18. August 2020 16:05 ET
|
Equillium
LA JOLLA, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Announces Pricing of Public Offering of Common Stock
13. August 2020 21:42 ET
|
Equillium
LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Announces Proposed Public Offering of Common Stock
13. August 2020 16:02 ET
|
Equillium
LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights
12. August 2020 08:37 ET
|
Equillium
LA JOLLA, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study
10. August 2020 16:07 ET
|
Equillium
Complete response observed in five of seven patients in first two dose cohorts COVID-19 Pre-IND meeting request and briefing package submitted to the FDA LA JOLLA, Calif., Aug. 10, 2020 (GLOBE...
Equillium to Present at BTIG Virtual Biotechnology Conference 2020
30. Juli 2020 16:07 ET
|
Equillium
LA JOLLA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...